LDX logo

Lumos Diagnostics Holdings CHIA:LDX Stock Report

Last Price

AU$0.033

Market Cap

AU$24.7m

7D

-21.4%

1Y

-57.7%

Updated

01 Feb, 2025

Data

Company Financials

Lumos Diagnostics Holdings Limited

CHIA:LDX Stock Report

Market Cap: AU$24.7m

LDX Stock Overview

Develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. More details

LDX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Lumos Diagnostics Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lumos Diagnostics Holdings
Historical stock prices
Current Share PriceAU$0.033
52 Week HighAU$0.093
52 Week LowAU$0.028
Beta0.76
1 Month Change-10.81%
3 Month Change-5.71%
1 Year Change-57.69%
3 Year Change-96.78%
5 Year Changen/a
Change since IPO-97.56%

Recent News & Updates

Recent updates

Shareholder Returns

LDXAU Medical EquipmentAU Market
7D-21.4%0.7%1.4%
1Y-57.7%8.2%9.2%

Return vs Industry: LDX underperformed the Australian Medical Equipment industry which returned 8.2% over the past year.

Return vs Market: LDX underperformed the Australian Market which returned 9.2% over the past year.

Price Volatility

Is LDX's price volatile compared to industry and market?
LDX volatility
LDX Average Weekly Movement13.2%
Medical Equipment Industry Average Movement10.3%
Market Average Movement7.9%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market3.0%

Stable Share Price: LDX's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: LDX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2018n/aDoug Wardlumosdiagnostics.com

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers.

Lumos Diagnostics Holdings Limited Fundamentals Summary

How do Lumos Diagnostics Holdings's earnings and revenue compare to its market cap?
LDX fundamental statistics
Market capAU$24.70m
Earnings (TTM)-AU$13.83m
Revenue (TTM)AU$17.91m

1.4x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LDX income statement (TTM)
RevenueUS$11.13m
Cost of RevenueUS$4.57m
Gross ProfitUS$6.56m
Other ExpensesUS$15.16m
Earnings-US$8.59m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.011
Gross Margin58.96%
Net Profit Margin-77.19%
Debt/Equity Ratio0%

How did LDX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 01:11
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lumos Diagnostics Holdings Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroBell Potter
Shane StoreyWilsons Advisory and Stockbroking Ltd.